Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Equillium Inc (EQ)
NASDAQ:EQ
EQ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.49 - $3.25
Previous CloseN/A
Volume484.47K
Average Volume (3M)1.53M
Market Cap
$32.28M
Enterprise Value$4.09M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Mar 26, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding35,430,763
10 Day Avg. Volume4,282,763
30 Day Avg. Volume1,533,023
Standard Deviation0.45
R-Squared0.04
Alpha0.00180
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.69
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.11
Enterprise Value/Ebitda-0.79
Forecast
1Y Price Target
$2.00Price Target Upside124.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Equillium News
PremiumCompany Announcements
Equillium Announces Board and Audit Committee Changes
PremiumCompany Announcements
Equillium’s Q3 Financials and Clinical Progress in Focus
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEQ reported positive topline results from a Phase 2 study of lead asset itolizumab in ulcerative colitis, demonstrating encouraging activity and being well tolerated with no notable safety signals.
Regulatory ProgressEquillium received a positive recommendation from the Independent Data Monitoring Committee (IDMC) based on its review of the interim results from the Phase 3 EQUATOR study evaluating itolizumab in subjects with acute graft-versus-host disease.
Strategic FocusEQ will retain development and commercial rights for itolizumab in the US/Canada/Australia/New Zealand regions and will prioritize itolizumab as their lead asset with two key data readouts expected.
Bears Say
Financial RiskRisks include, but are not limited to: delays in generating clinical data with itolizumab, refusal by Ono to exercise its option on itolizumab, failure to obtain approval for itolizumab, clinical setbacks with other pipeline programs, notably EQ-101 and EQ-102, and possible medium-term dilution risk.
Partnership DecisionsOno Pharmaceutical decided not to exercise its option to acquire itolizumab based on strategic reasons.
Pipeline FocusEQ has paused further activities on earlier pipeline assets to conserve cash, including EQ101 in alopecia areata and the preclinical oral peptide EQ302.
---
Ownership Overview
40.11% Insiders
2.87% Mutual Funds
19.79% Other Institutional Investors
34.81% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EQ FAQ
What was Equillium Inc’s price range in the past 12 months?
Equillium Inc lowest stock price was $0.49 and its highest was $3.25 in the past 12 months.
What is Equillium Inc’s market cap?
Equillium Inc’s market cap is $32.28M.
When is Equillium Inc’s upcoming earnings report date?
Equillium Inc’s upcoming earnings report date is Mar 26, 2025 which is in 32 days.
How were Equillium Inc’s earnings last quarter?
Equillium Inc released its earnings results on Nov 13, 2024. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.018 by -$0.018.
Is Equillium Inc overvalued?
According to Wall Street analysts Equillium Inc’s price is currently Undervalued.
Does Equillium Inc pay dividends?
Equillium Inc does not currently pay dividends.
What is Equillium Inc’s EPS estimate?
Equillium Inc’s EPS estimate is -0.31.
How many shares outstanding does Equillium Inc have?
Equillium Inc has 35,430,763 shares outstanding.
What happened to Equillium Inc’s price movement after its last earnings report?
Equillium Inc reported an EPS of $0 in its last earnings report, missing expectations of $0.018. Following the earnings report the stock price went down -12.821%.
Which hedge fund is a major shareholder of Equillium Inc?
Currently, no hedge funds are holding shares in EQ
---
Equillium Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (124.72% Upside)
$2.00 (124.72% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.42%
12-Months-Change
Fundamentals
Return on Equity
-19.52%
Trailing 12-Months
Asset Growth
-37.61%
Trailing 12-Months
Company Description
Equillium Inc
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline include EQ001, is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.
---
EQ Stock 12 Month Forecast
Average Price Target
$2.00
▲(124.72% Upside)
Technical Analysis
Amicus
―
Arrowhead Pharmaceuticals
―
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering EQ
1 Year
1 Year Success Rate
6/19 ratings generated profit
1 Year Average Return
-0.74%
reiterated a buy rating 16 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 31.58% of your transactions generating a profit, with an average return of -0.74% per trade.
---